BTAI
BioXcel Therapeutics, Inc.
$1.11
0.00%
$34.1M
No data for this timeframe.
Vol
Market Cap$34.1M
Cap SizeNano Cap
Analyst ConsensusStrong Buy (82%)
Inst. Holders5 funds
Inst. Value$624.5K
Inst. Activity1 buys / 3 sells
Insider Activity0B / 4S
Insider Net $-$43.1K
SEC Reports6
Press Releases2
Recent Activity
Nov 14, 2026
fda_pdufa
PDUFA: BTAI — IGALMI in acute agitation associated with bipolar disorders or schizophrenia in the at-home setting — 2026-11-14
FDA target action date 2026-11-14 for BTAI (BioXcel Therapeutics, Inc.). Drug: IGALMI. Indication: a
May 22, 2026
SEC
Three top insiders at BioXcel Therapeutics (CEO, CFO, and another executive) collectively sold $35.6K in open-market sha
CLUSTER — Impact 5/10
May 20, 2026
SEC
Richard I. Steinhart, an officer of BioXcel Therapeutics, filed a Form 144 to sell 6,845 shares of common stock valued a
144 — Impact 2/10
May 20, 2026
Insider
Mehta Vimal sold 19,419 shares
CEO and President @ $1.09 ($21.1K)
May 20, 2026
Insider
Steinhart Richard I sold 6,845 shares
Chief Financial Officer @ $1.09 ($7.4K)
May 20, 2026
Insider
Rodriguez Javier sold 6,560 shares
See Remarks @ $1.08 ($7.1K)
May 15, 2026
SEC
BioXcel Therapeutics reported Q1 2026 revenue of $206K (up 22.6% YoY from $168K) and a GAAP net loss of $12.7M ($0.54/sh
8-K — Impact 6/10
Inst.
VANGUARD GROUP INC — ADD
292,753 shares ($468.4K)
Price Targets
$14.00
+1208.4% upside
Strong Buy
Current $1.07
Low $1.00
Median $8.50
High $38.00
4 analysts
$1.00
$38.00
Analyst Ratings
2Strong Buy
7Buy
1Hold
1Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 2, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Mar 17, 2026 | Rodman & Renshaw | INITIATE | Buy |
| Mar 5, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.58 ▼ -58.9% | $-0.58 — $-0.58 | 76% YoY | 1 |
| Next Q | $-0.97 ▼ -203.1% | $-0.97 — $-0.97 | 55% YoY | 1 |
| Current FY | $-2.62 ▼ -33.9% | $-2.62 — $-2.62 | 54% YoY | 1 |
| Next FY | $-1.54 ▲ +6.7% | $-2.05 — $-1.12 | 41% YoY | 3 |
Latest Reports
BEARISH
CLUSTER
5/10
Three top insiders at BioXcel Therapeutics (CEO, CFO, and another executive) collectively sold $35.6K in open-market sha
May 22, 2026
NEUTRAL
144
2/10
Richard I. Steinhart, an officer of BioXcel Therapeutics, filed a Form 144 to sell 6,845 shares of common stock valued a
May 20, 2026
MIXED
Press
6/10
BioXcel Therapeutics reported declining IGALMI revenue for Q4 and full-year 2025, with net revenue down significantly ye
Mar 27, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $468.4K | ADD |
| FMR LLC | $144.5K | TRIM |
| WELLS FARGO & COMPANY/MN | $6.9K | TRIM |
| MORGAN STANLEY | $2.3K | TRIM |
| BANK OF AMERICA CORP | $2.3K | NEAR_EXIT |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 20, 2026 | Mehta Vimal | SELL | $21.1K |
| May 20, 2026 | Steinhart Richard | SELL | $7.4K |
| May 20, 2026 | Rodriguez Javier | SELL | $7.1K |
| May 20, 2026 | Yocca Frank | SELL | $7.4K |
| May 4, 2026 | Yocca Frank | M | $0.00 |
5 institutional holders with $624.5K total value (390,288 shares) as of 2025-Q4. Top holders: VANGUARD, FMR, WELLS. Net selling activity: 3 institutions trimmed/exited vs 1 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 292,753 | $468.4K | 75.0% | ADD +52.4% |
| 2 | FMR LLC | 90,300 | $144.5K | 23.1% | TRIM -54.5% |
| 3 | WELLS FARGO & COMPANY/MN | 4,325 | $6.9K | 1.1% | TRIM -73.5% |
| 4 | MORGAN STANLEY | 1,464 | $2.3K | 0.4% | TRIM -36.5% |
| 5 | BANK OF AMERICA CORP /DE/ | 1,446 | $2.3K | 0.4% | NEAR_EXIT -79.0% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | ADD | 192,125 | 292,753 | +52.4% | $468.4K | 2025-Q4 |
| FMR LLC | TRIM | 198,600 | 90,300 | -54.5% | $144.5K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | TRIM | 16,316 | 4,325 | -73.5% | $6.9K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 6,881 | 1,446 | -79.0% | $2.3K | 2025-Q4 |
| FMR LLC | NEW | — | 198,600 | — | $508.4K | 2025-Q3 |
| VANGUARD GROUP INC | DOUBLED | 18,824 | 192,125 | +920.6% | $491.8K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 1,547 | 6,881 | +344.8% | $17.6K | 2025-Q3 |
| UBS Group AG | TRIM | 101,778 | 39,882 | -60.8% | $72.2K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | ADD | 12,293 | 16,919 | +37.6% | $30.6K | 2025-Q2 |
| UBS Group AG | NEW | — | 101,778 | — | $206.6K | 2025-Q1 |
| VANGUARD GROUP INC | NEW | — | 18,824 | — | $38.2K | 2025-Q1 |
| WELLS FARGO & COMPANY/MN | NEW | — | 12,293 | — | $25.0K | 2025-Q1 |
| VANGUARD GROUP INC | EXIT | 1,187,466 | 0 | -100.0% | $0.00 | 2025-Q1 |
| UBS Group AG | EXIT | 1,276,893 | 0 | -100.0% | $0.00 | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 77,900 | 0 | -100.0% | $0.00 | 2025-Q1 |
| CITADEL ADVISORS LLC | EXIT | 93,900 | 0 | -100.0% | $0.00 | 2025-Q1 |
| WELLS FARGO & COMPANY/MN | EXIT | 199,010 | 0 | -100.0% | $0.00 | 2025-Q1 |
| UBS Group AG | DOUBLED | 13,228 | 1,276,893 | +9553.0% | $477.6K | 2024-Q4 |
| CITADEL ADVISORS LLC | ADD | 49,900 | 93,900 | +88.2% | $35.1K | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 129,869 | 77,900 | -40.0% | $29.1K | 2024-Q4 |
| MORGAN STANLEY | TRIM | 40,614 | 25,796 | -36.5% | $9.6K | 2024-Q4 |
| MORGAN STANLEY | TRIM | 116,563 | 40,614 | -65.2% | $24.8K | 2024-Q3 |
4 unique insiders with 4 transactions. Net insider value: -$43.1K ($0.00 bought, $43.1K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 20, 2026 | Mehta Vimal | CEO and President | SELL | 19,419 | $1.09 | $21.1K |
| May 20, 2026 | Steinhart Richard I | Chief Financial Officer | SELL | 6,845 | $1.09 | $7.4K |
| May 20, 2026 | Rodriguez Javier | See Remarks | SELL | 6,560 | $1.08 | $7.1K |
| May 20, 2026 | Yocca Frank | Chief Scientific Officer | SELL | 6,845 | $1.09 | $7.4K |
| May 4, 2026 | Yocca Frank | Chief Scientific Officer | M | 17,500 | $0.00 | $0.00 |
| May 4, 2026 | Yocca Frank | Chief Scientific Officer | M | 17,500 | $0.00 | $0.00 |
| May 4, 2026 | Rodriguez Javier | See Remarks | M | 17,500 | $0.00 | $0.00 |
| May 4, 2026 | Rodriguez Javier | See Remarks | M | 17,500 | $0.00 | $0.00 |
| May 4, 2026 | Steinhart Richard I | Chief Financial Officer | M | 17,500 | $0.00 | $0.00 |
| May 4, 2026 | Steinhart Richard I | Chief Financial Officer | M | 17,500 | $0.00 | $0.00 |
| May 4, 2026 | Mehta Vimal | CEO and President | M | 49,758 | $0.00 | $0.00 |
| May 4, 2026 | Mehta Vimal | CEO and President | M | 49,758 | $0.00 | $0.00 |
| May 1, 2026 | Mehta Vimal | CEO and President | M | 18,000 | $0.00 | $0.00 |
| May 1, 2026 | Mehta Vimal | CEO and President | M | 18,000 | $0.00 | $0.00 |
| May 1, 2026 | Steinhart Richard I | Chief Financial Officer | M | 9,000 | $0.00 | $0.00 |
| May 1, 2026 | Steinhart Richard I | Chief Financial Officer | M | 9,000 | $0.00 | $0.00 |
| May 1, 2026 | Yocca Frank | Chief Scientific Officer | M | 9,000 | $0.00 | $0.00 |
| May 1, 2026 | Yocca Frank | Chief Scientific Officer | M | 9,000 | $0.00 | $0.00 |
| May 1, 2026 | Rodriguez Javier | See Remarks | M | 9,000 | $0.00 | $0.00 |
| May 1, 2026 | Rodriguez Javier | See Remarks | M | 9,000 | $0.00 | $0.00 |
| Mar 15, 2026 | Mehta Vimal | CEO and President | M | 219 | $0.00 | $0.00 |
| Mar 15, 2026 | Mehta Vimal | CEO and President | M | 219 | $0.00 | $0.00 |
| Mar 15, 2026 | Rodriguez Javier | See Remarks | M | 35 | $0.00 | $0.00 |
| Mar 15, 2026 | Rodriguez Javier | See Remarks | M | 35 | $0.00 | $0.00 |
| Mar 15, 2026 | Yocca Frank | Chief Scientific Officer | M | 35 | $0.00 | $0.00 |
| Mar 15, 2026 | Yocca Frank | Chief Scientific Officer | M | 35 | $0.00 | $0.00 |
| Mar 15, 2026 | Steinhart Richard I | Chief Financial Officer | M | 35 | $0.00 | $0.00 |
| Mar 15, 2026 | Steinhart Richard I | Chief Financial Officer | M | 35 | $0.00 | $0.00 |
| Mar 14, 2026 | Mehta Vimal | CEO and President | M | 164 | $0.00 | $0.00 |
| Mar 14, 2026 | Mehta Vimal | CEO and President | M | 164 | $0.00 | $0.00 |
| Mar 14, 2026 | Steinhart Richard I | Chief Financial Officer | M | 33 | $0.00 | $0.00 |
| Mar 14, 2026 | Yocca Frank | Chief Scientific Officer | M | 33 | $0.00 | $0.00 |
| Mar 14, 2026 | Yocca Frank | Chief Scientific Officer | M | 33 | $0.00 | $0.00 |
| Mar 14, 2026 | Rodriguez Javier | See Remarks | M | 33 | $0.00 | $0.00 |
| Mar 14, 2026 | Rodriguez Javier | See Remarks | M | 33 | $0.00 | $0.00 |
| Mar 14, 2026 | Steinhart Richard I | Chief Financial Officer | M | 33 | $0.00 | $0.00 |
6 SEC filing reports analyzed. Sentiment: 0 bullish, 3 bearish, 0 mixed, 3 neutral. Avg impact: 4.7/10.
BEARISH
CLUSTER
5/10
Three top insiders at BioXcel Therapeutics (CEO, CFO, and another executive) collectively sold $35.6
May 22, 2026
NEUTRAL
144
2/10
Richard I. Steinhart, an officer of BioXcel Therapeutics, filed a Form 144 to sell 6,845 shares of c
May 20, 2026
NEUTRAL
8-K
6/10
BioXcel Therapeutics reported Q1 2026 revenue of $206K (up 22.6% YoY from $168K) and a GAAP net loss
May 15, 2026
BEARISH
PRESS-RELEASE
6/10
BioXcel Therapeutics reported Q1 2026 EPS of -$0.54 (GAAP) vs consensus -$0.48, a -12.5% miss, with
May 15, 2026
BEARISH
8-K
6/10
BioXcel Therapeutics issued warrants to purchase 1,353,729 shares of common stock to its lenders as
Apr 17, 2026
NEUTRAL
8-K
3/10
Analysis based on filing metadata only — document content was unavailable. The filing is an 8-K with
Mar 11, 2026
Current analyst consensus: Strong Buy (82% buy). Based on 11 analysts: 2 strong buy, 7 buy, 1 hold, 1 sell, 0 strong sell.
Analyst Price Targets
$14.00 mean target
+1208.4% upside
Strong Buy (3.00)
$1.00 Low
$38.00 High
| Metric | Value |
|---|---|
| Current Price | $1.07 |
| Target Low | $1.00 |
| Target Mean | $14.00 |
| Target Median | $8.50 |
| Target High | $38.00 |
| # Analysts | 4 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.58 | $-0.58 | $-0.58 | 76.3% | -58.9% | — | $0.0B | 41.0% | 1 |
| Next Q 2026-09-30 |
$-0.97 | $-0.97 | $-0.97 | 55.2% | -203.1% | — | $0.0B | 95.3% | 1 |
| Current FY 2026-12-31 |
$-2.62 | $-2.62 | $-2.62 | 54.1% | -33.9% | 1↑ 0↓ | $0.0B | 19.9% | 1 |
| Next FY 2027-12-31 |
$-1.54 | $-2.05 | $-1.12 | 41.2% | +6.7% | 1↑ 0↓ | $0.0B | 2359.2% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.580 | |
| 7d ago | $-0.365 | -0.215 |
| 30d ago | $-0.365 | -0.215 |
| 60d ago | $-0.513 | -0.067 |
| 90d ago | $-0.563 | -0.017 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 2, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 17, 2026 | Rodman & Renshaw | INITIATE | — | Buy |
| Mar 5, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 7 | 1 | 1 | 0 | 82% | |
| May 1, 2026 | 2 | 7 | 1 | 1 | 0 | 82% | |
| Apr 1, 2026 | 2 | 7 | 1 | 1 | 0 | 82% | |
| Mar 1, 2026 | 2 | 7 | 1 | 1 | 0 | 82% | |
| Feb 1, 2026 | 2 | 7 | 1 | 1 | 0 | 82% | |
| Jan 1, 2026 | 2 | 7 | 1 | 1 | 0 | 82% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
Recent Reddit Threads
$btai could be a ghost one
▲ 1
💬 0
⚡ 0.0
Nov 14, 2026
fda_pdufa
PDUFA: BTAI — IGALMI in acute agitation associated with bipolar disorders or schizophrenia in the at-home setting — 2026-11-14
FDA target action date 2026-11-14 for BTAI (BioXcel Therapeutics, Inc.). Drug: IGALMI. Indication: acute agitation associated with bipolar disorders o
Jun 5, 2026
short_volume
Short Volume: BTAI — 80.3% short (0.5M / 0.6M)
Short: 498,512 | Exempt: 23,988 | TRF Vol: 620,691 | Short Ratio: 80.3% | Off-exchange volume (dark pool + OTC)
Jun 4, 2026
Clinical Trial
Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder
Phase Phase 3 — COMPLETED
Jun 4, 2026
Clinical Trial
Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia
Phase Phase 3 — COMPLETED
Jun 3, 2026
Clinical Trial
An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associated With Dementia
Phase Phase 2 — TERMINATED
Jun 3, 2026
Clinical Trial
Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal
Phase Phase 2 — COMPLETED
Jun 3, 2026
Clinical Trial
Sub-Lingual Dexmedetomidine in Agitation Associated With Dementia
Phase Phase 2 — COMPLETED
May 29, 2026
short_volume
Short Volume: BTAI — 57.3% short (0.4M / 0.7M)
Short: 389,633 | Exempt: 16,497 | TRF Vol: 679,700 | Short Ratio: 57.3% | Off-exchange volume (dark pool + OTC)
May 27, 2026
short_volume
Short Volume: BTAI — 62.8% short (0.6M / 0.9M)
Short: 587,880 | Exempt: 32,845 | TRF Vol: 936,211 | Short Ratio: 62.8% | Off-exchange volume (dark pool + OTC)
May 15, 2026
earnings
BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
<p align="center"><em>FDA accepted sNDA for IGALMI® use in at-home (outpatient) setting; set Nov. 14, 2026, as PDUFA date </em></p>
May 13, 2026
earnings_calendar
BTAI Q1 2026 Earnings Scheduled — 2026-05-13
May 11, 2026
earnings_calendar
BTAI Q1 2026 Earnings Scheduled — 2026-05-11
Apr 17, 2026
other
BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting
<p align="center"><em>Live event to be held on Thursday, April 23, at 2:00 p.m. ET </em></p>
Apr 16, 2026
short_volume
Short Volume: BTAI — 65.6% short (0.4M / 0.7M)
Short: 434,265 | Exempt: 4,394 | TRF Vol: 661,625 | Short Ratio: 65.6% | Off-exchange volume (dark pool + OTC)
Apr 10, 2026
short_volume
Short Volume: BTAI — 65.7% short (0.3M / 0.5M)
Short: 347,748 | Exempt: 440 | TRF Vol: 529,698 | Short Ratio: 65.7% | Off-exchange volume (dark pool + OTC)
Apr 8, 2026
other
BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions
<p align="center"><em>DoW-funded Phase 2a trial led by University of North Carolina at Chapel Hill (UNC) Institute for Trauma Recovery </em></p>
Apr 7, 2026
short_volume
Short Volume: BTAI — 63.9% short (0.4M / 0.6M)
Short: 410,066 | Exempt: 3,653 | TRF Vol: 641,332 | Short Ratio: 63.9% | Off-exchange volume (dark pool + OTC)
Apr 6, 2026
short_volume
Short Volume: BTAI — 70.6% short (0.4M / 0.5M)
Short: 353,393 | Exempt: 34,054 | TRF Vol: 500,347 | Short Ratio: 70.6% | Off-exchange volume (dark pool + OTC)
Apr 1, 2026
other
BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting
<p align="center"><em>PDUFA target action date of November 14, 2026</em></p>
Mar 30, 2026
short_volume
Short Volume: BTAI — 67.9% short (0.4M / 0.5M)
Short: 371,862 | Exempt: 188 | TRF Vol: 547,279 | Short Ratio: 67.9% | Off-exchange volume (dark pool + OTC)